Chesapeake Urology Research Associates

Hanover, Maryland 21076

4 studies enrolling now · 17 studies all time

What they study most

BCG-Unresponsive Bladder Cancer, Benign Prostatic Hyperplasia, Bladder Cancer, Bladder Neoplasm, Bladder Tumors, Cancer of Bladder, Cancer of the Bladder, Cancer of the Bladder, Recurrent, Carcinoma in Situ of Bladder, Hematuria, Hematuria - Cause Not Known, High-Risk Non-Muscle-Invasive Bladder Cancer

Studies at this site

• LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve — Recruiting now
• A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer — Recruiting now
• A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer — Recruiting now
• Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine. — Recruiting now
• Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer — Recruiting now
• Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC — Recruiting now
• Optilume™ BPH Catheter System in Men With Symptomatic BPH — Running, not enrolling
• A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC) — Running, not enrolling
• CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer — Running, not enrolling
• A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer — Running, not enrolling
• A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer — Running, not enrolling
• A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy — Completed
• A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer — Stopped early
• Xenform Postmarket Surveillance Study — Completed
• A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB) — Completed
• Post Market Study Of Single Incision Sling Versus Transobturator Sling for Stress Urinary Incontinence — Completed
• Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tumors. — Stopped early